- Home
- HY vs GYRE Comparison
HY vs GYRE Comparison
Compare HY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- GYRE
- Stock Information
- Founded
- HY 1991
- GYRE 2002
- Country
- HY United States
- GYRE United States
- Employees
- HY 8600
- GYRE N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- GYRE Health Care
- Exchange
- HY Nasdaq
- GYRE Nasdaq
- Market Cap
- HY 911.0M
- GYRE 997.3M
- IPO Year
- HY N/A
- GYRE N/A
- Fundamental
- Price
- HY $51.98
- GYRE $11.54
- Analyst Decision
- HY Strong Buy
- GYRE
- Analyst Count
- HY 2
- GYRE 0
- Target Price
- HY $80.00
- GYRE N/A
- AVG Volume (30 Days)
- HY 53.4K
- GYRE 52.5K
- Earning Date
- HY 02-25-2025
- GYRE 03-25-2025
- Dividend Yield
- HY 2.69%
- GYRE N/A
- EPS Growth
- HY 41.25
- GYRE N/A
- EPS
- HY 8.90
- GYRE N/A
- Revenue
- HY $4,267,899,999.00
- GYRE $105,033,000.00
- Revenue This Year
- HY $6.62
- GYRE $25.32
- Revenue Next Year
- HY N/A
- GYRE $12.95
- P/E Ratio
- HY $5.85
- GYRE N/A
- Revenue Growth
- HY 4.70
- GYRE N/A
- 52 Week Low
- HY $48.73
- GYRE $8.26
- 52 Week High
- HY $84.44
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- HY 45.46
- GYRE 47.99
- Support Level
- HY $51.04
- GYRE $12.09
- Resistance Level
- HY $54.76
- GYRE $12.80
- Average True Range (ATR)
- HY 1.22
- GYRE 0.56
- MACD
- HY 0.02
- GYRE -0.00
- Stochastic Oscillator
- HY 27.09
- GYRE 16.39
About HY Hyster-Yale Materials Handling Inc.
Hyster-Yale Materials Handling Inc designs, engineers, manufactures, sells, and services a line of lift trucks and aftermarket parts. It manufactures components, such as frames, masts, and transmissions; and assembles lift trucks and the products are market under the Hyster and Yale brand names to independent Hyster and Yale retail dealerships. The company operates through three geographical regions namely: the Americas, EMEA, JAPIC, of which Americas accounts for the larger share of the revenue.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.